Unknownn的个人主页 - 老虎社区

Unknownn

Unknownn

暂无个人介绍

IP属地：未知

5关注

2粉丝

0主题

0勋章

2021-11-29

Up more

Big tech shares jumped in morning trading<blockquote>大型科技股早盘上涨</blockquote>

2021-11-16

Ok

Report says drugmakers impose unjustified U.S. price increases; spending on AbbVie drug rises $1.4 billion<blockquote>报告称制药商在美国不合理地涨价；艾伯维药物支出增加14亿美元</blockquote>

2021-11-16

Nice

Report says drugmakers impose unjustified U.S. price increases; spending on AbbVie drug rises $1.4 billion<blockquote>报告称制药商在美国不合理地涨价；艾伯维药物支出增加14亿美元</blockquote>

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4100087245977920","uuid":"4100087245977920","gmtCreate":1637070218744,"gmtModify":1637071843970,"name":"Unknownn","pinyin":"unknownn","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/abc4f174c588f5a6be0547639a148c56","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":5,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":600716496,"gmtCreate":1638197483029,"gmtModify":1638197483104,"author":{"id":"4100087245977920","authorId":"4100087245977920","name":"Unknownn","avatar":"https://static.tigerbbs.com/abc4f174c588f5a6be0547639a148c56","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100087245977920","authorIdStr":"4100087245977920"},"themes":[],"htmlText":"Up more","listText":"Up more","text":"Up more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/600716496","repostId":"1182524223","repostType":4,"repost":{"id":"1182524223","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638197006,"share":"https://www.laohu8.com/m/news/1182524223?lang=zh_CN&edition=full","pubTime":"2021-11-29 22:43","market":"us","language":"en","title":"Big tech shares jumped in morning trading<blockquote>大型科技股早盘上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1182524223","media":"Tiger Newspress","summary":"Big tech shares jumped in morning trading.Apple,Microsoft,Amazon,Alphabet and Meta Platforms climbed","content":"<p>Big tech shares jumped in morning trading.Apple,Microsoft,Amazon,Alphabet&nbsp;and&nbsp;Meta&nbsp;Platforms&nbsp;climbed between 1% and 2%.</p><p><blockquote>大型科技股早盘上涨。苹果、微软、亚马逊、Alphabet和Meta Platforms上涨1%至2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/e646cfb67f62c007db16ed52e6712cd4\" tg-width=\"406\" tg-height=\"299\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Big tech shares jumped in morning trading<blockquote>大型科技股早盘上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBig tech shares jumped in morning trading<blockquote>大型科技股早盘上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 22:43</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Big tech shares jumped in morning trading.Apple,Microsoft,Amazon,Alphabet&nbsp;and&nbsp;Meta&nbsp;Platforms&nbsp;climbed between 1% and 2%.</p><p><blockquote>大型科技股早盘上涨。苹果、微软、亚马逊、Alphabet和Meta Platforms上涨1%至2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/e646cfb67f62c007db16ed52e6712cd4\" tg-width=\"406\" tg-height=\"299\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","FB":"ProShares S&P 500 Dynamic Buffer ETF","AAPL":"苹果","GOOGL":"谷歌A","MSFT":"微软"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182524223","content_text":"Big tech shares jumped in morning trading.Apple,Microsoft,Amazon,Alphabet and Meta Platforms climbed between 1% and 2%.","news_type":1,"symbols_score_info":{"AAPL":0.9,"GOOGL":0.9,"AMZN":0.9,"FB":0.9,"MSFT":0.9}},"isVote":1,"tweetType":1,"viewCount":1080,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871674052,"gmtCreate":1637070595727,"gmtModify":1637070872794,"author":{"id":"4100087245977920","authorId":"4100087245977920","name":"Unknownn","avatar":"https://static.tigerbbs.com/abc4f174c588f5a6be0547639a148c56","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100087245977920","authorIdStr":"4100087245977920"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871674052","repostId":"1115914926","repostType":4,"repost":{"id":"1115914926","kind":"news","pubTimestamp":1637065849,"share":"https://www.laohu8.com/m/news/1115914926?lang=zh_CN&edition=full","pubTime":"2021-11-16 20:30","market":"us","language":"en","title":"Report says drugmakers impose unjustified U.S. price increases; spending on AbbVie drug rises $1.4 billion<blockquote>报告称制药商在美国不合理地涨价；艾伯维药物支出增加14亿美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1115914926","media":"Reuters","summary":"Drugmakers hiked U.S. prices on seven of the 10 costliest prescription drugs in 2020 without justifi","content":"<p>Drugmakers hiked U.S. prices on seven of the 10 costliest prescription drugs in 2020 without justification, increasing drug spending by $1.67 billion, a U.S. group that reviews the value of medicines said on Tuesday.</p><p><blockquote>美国一个审查药品价值的组织周二表示，制药商在没有正当理由的情况下提高了2020年10种最昂贵处方药中的7种的美国价格，使药品支出增加了16.7亿美元。</blockquote></p><p> AbbVie Inc's(ABBV.N)widely used Humira rheumatoid arthritis drug accounted for the majority of the spending increase, with a net price increase of 9.6% leading to an almost $1.4 billion increase in U.S. spending.</p><p><blockquote>艾伯维公司（ABBV.N）广泛使用的Humira类风湿性关节炎药物占支出增长的大部分，净价格上涨9.6%，导致美国支出增加近14亿美元。</blockquote></p><p> The Boston-based Institute for Clinical and Economic Review (ICER) said in a report that after reviewing published studies and input from drug manufacturers it found no evidence of new clinical benefits to justify the price hikes.</p><p><blockquote>总部位于波士顿的临床和经济评论研究所（ICER）在一份报告中表示，在审查了已发表的研究和药品制造商的意见后，没有发现新的临床益处的证据来证明价格上涨的合理性。</blockquote></p><p> \"Several of these treatments have been on the market for many years, with scant evidence that they are any more effective than we understood them to be years ago when they cost far less,\" said ICER Chief Medical Officer David Rind.</p><p><blockquote>ICER首席医疗官David Rind表示：“其中一些治疗方法已经上市多年，几乎没有证据表明它们比我们多年前认为的更有效，当时它们的成本要低得多。”</blockquote></p><p> \"The most extreme of these is Humira, with an ever-escalating U.S. price that contrasts starkly to its falling price in every country where Humira currently faces biosimilar competition,\" he said in a statement. Humira received U.S. regulatory approval in 2002.</p><p><blockquote>他在一份声明中表示：“其中最极端的是修美乐，美国的价格不断上涨，与修美乐目前面临生物仿制药竞争的每个国家的价格下降形成鲜明对比。”Humira于2002年获得美国监管机构的批准。</blockquote></p><p> AbbVie said in a response to ICER that the report lacked context because ICER does not perform full value assessments and excludes evidence from smaller patient populations.</p><p><blockquote>艾伯维在回应ICER时表示，该报告缺乏背景，因为ICER没有进行全面的价值评估，并排除了来自较小患者群体的证据。</blockquote></p><p> The findings come as President Joe Biden and Democrats in Congress attempt to push through legislation that would lower drug prices by allowing the federal government to negotiate drug payments by Medicare, which covers Americans aged 65 and older.</p><p><blockquote>调查结果公布之际，美国总统乔·拜登和国会民主党人正试图推动立法，通过允许联邦政府通过医疗保险谈判药品支付来降低药品价格，医疗保险覆盖65岁及以上的美国人。</blockquote></p><p> The United States spends more than twice as much per person on drugs as other wealthy economies, about $1,500, for a total of around $350 billion in 2019.</p><p><blockquote>美国人均在毒品上的支出是其他富裕经济体的两倍多，约为1500美元，2019年总额约为3500亿美元。</blockquote></p><p> Novartis(NOVN.S)drug Promacta, which is used to treat the rare blood disorder severe aplastic anemia (SAA), saw the highest increase in net price at 14.1%, leading to a $100 million increase in U.S. spending.</p><p><blockquote>诺华（NOVN.S）用于治疗罕见血液疾病重度再生障碍性贫血（SAA）的药物Promacta净价涨幅最高，为14.1%，导致美国支出增加1亿美元。</blockquote></p><p> Novartis said it takes a value-based pricing approach and that it provided ICER with significant new clinical and health economic data that the group did not take into account.</p><p><blockquote>诺华表示，它采用基于价值的定价方法，并向ICER提供了该集团未考虑的重要新临床和健康经济数据。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Report says drugmakers impose unjustified U.S. price increases; spending on AbbVie drug rises $1.4 billion<blockquote>报告称制药商在美国不合理地涨价；艾伯维药物支出增加14亿美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReport says drugmakers impose unjustified U.S. price increases; spending on AbbVie drug rises $1.4 billion<blockquote>报告称制药商在美国不合理地涨价；艾伯维药物支出增加14亿美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-16 20:30</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Drugmakers hiked U.S. prices on seven of the 10 costliest prescription drugs in 2020 without justification, increasing drug spending by $1.67 billion, a U.S. group that reviews the value of medicines said on Tuesday.</p><p><blockquote>美国一个审查药品价值的组织周二表示，制药商在没有正当理由的情况下提高了2020年10种最昂贵处方药中的7种的美国价格，使药品支出增加了16.7亿美元。</blockquote></p><p> AbbVie Inc's(ABBV.N)widely used Humira rheumatoid arthritis drug accounted for the majority of the spending increase, with a net price increase of 9.6% leading to an almost $1.4 billion increase in U.S. spending.</p><p><blockquote>艾伯维公司（ABBV.N）广泛使用的Humira类风湿性关节炎药物占支出增长的大部分，净价格上涨9.6%，导致美国支出增加近14亿美元。</blockquote></p><p> The Boston-based Institute for Clinical and Economic Review (ICER) said in a report that after reviewing published studies and input from drug manufacturers it found no evidence of new clinical benefits to justify the price hikes.</p><p><blockquote>总部位于波士顿的临床和经济评论研究所（ICER）在一份报告中表示，在审查了已发表的研究和药品制造商的意见后，没有发现新的临床益处的证据来证明价格上涨的合理性。</blockquote></p><p> \"Several of these treatments have been on the market for many years, with scant evidence that they are any more effective than we understood them to be years ago when they cost far less,\" said ICER Chief Medical Officer David Rind.</p><p><blockquote>ICER首席医疗官David Rind表示：“其中一些治疗方法已经上市多年，几乎没有证据表明它们比我们多年前认为的更有效，当时它们的成本要低得多。”</blockquote></p><p> \"The most extreme of these is Humira, with an ever-escalating U.S. price that contrasts starkly to its falling price in every country where Humira currently faces biosimilar competition,\" he said in a statement. Humira received U.S. regulatory approval in 2002.</p><p><blockquote>他在一份声明中表示：“其中最极端的是修美乐，美国的价格不断上涨，与修美乐目前面临生物仿制药竞争的每个国家的价格下降形成鲜明对比。”Humira于2002年获得美国监管机构的批准。</blockquote></p><p> AbbVie said in a response to ICER that the report lacked context because ICER does not perform full value assessments and excludes evidence from smaller patient populations.</p><p><blockquote>艾伯维在回应ICER时表示，该报告缺乏背景，因为ICER没有进行全面的价值评估，并排除了来自较小患者群体的证据。</blockquote></p><p> The findings come as President Joe Biden and Democrats in Congress attempt to push through legislation that would lower drug prices by allowing the federal government to negotiate drug payments by Medicare, which covers Americans aged 65 and older.</p><p><blockquote>调查结果公布之际，美国总统乔·拜登和国会民主党人正试图推动立法，通过允许联邦政府通过医疗保险谈判药品支付来降低药品价格，医疗保险覆盖65岁及以上的美国人。</blockquote></p><p> The United States spends more than twice as much per person on drugs as other wealthy economies, about $1,500, for a total of around $350 billion in 2019.</p><p><blockquote>美国人均在毒品上的支出是其他富裕经济体的两倍多，约为1500美元，2019年总额约为3500亿美元。</blockquote></p><p> Novartis(NOVN.S)drug Promacta, which is used to treat the rare blood disorder severe aplastic anemia (SAA), saw the highest increase in net price at 14.1%, leading to a $100 million increase in U.S. spending.</p><p><blockquote>诺华（NOVN.S）用于治疗罕见血液疾病重度再生障碍性贫血（SAA）的药物Promacta净价涨幅最高，为14.1%，导致美国支出增加1亿美元。</blockquote></p><p> Novartis said it takes a value-based pricing approach and that it provided ICER with significant new clinical and health economic data that the group did not take into account.</p><p><blockquote>诺华表示，它采用基于价值的定价方法，并向ICER提供了该集团未考虑的重要新临床和健康经济数据。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/report-says-drugmakers-impose-unjustified-us-price-increases-spending-abbvie-2021-11-16/\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/report-says-drugmakers-impose-unjustified-us-price-increases-spending-abbvie-2021-11-16/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115914926","content_text":"Drugmakers hiked U.S. prices on seven of the 10 costliest prescription drugs in 2020 without justification, increasing drug spending by $1.67 billion, a U.S. group that reviews the value of medicines said on Tuesday.\nAbbVie Inc's(ABBV.N)widely used Humira rheumatoid arthritis drug accounted for the majority of the spending increase, with a net price increase of 9.6% leading to an almost $1.4 billion increase in U.S. spending.\nThe Boston-based Institute for Clinical and Economic Review (ICER) said in a report that after reviewing published studies and input from drug manufacturers it found no evidence of new clinical benefits to justify the price hikes.\n\"Several of these treatments have been on the market for many years, with scant evidence that they are any more effective than we understood them to be years ago when they cost far less,\" said ICER Chief Medical Officer David Rind.\n\"The most extreme of these is Humira, with an ever-escalating U.S. price that contrasts starkly to its falling price in every country where Humira currently faces biosimilar competition,\" he said in a statement. Humira received U.S. regulatory approval in 2002.\nAbbVie said in a response to ICER that the report lacked context because ICER does not perform full value assessments and excludes evidence from smaller patient populations.\nThe findings come as President Joe Biden and Democrats in Congress attempt to push through legislation that would lower drug prices by allowing the federal government to negotiate drug payments by Medicare, which covers Americans aged 65 and older.\nThe United States spends more than twice as much per person on drugs as other wealthy economies, about $1,500, for a total of around $350 billion in 2019.\nNovartis(NOVN.S)drug Promacta, which is used to treat the rare blood disorder severe aplastic anemia (SAA), saw the highest increase in net price at 14.1%, leading to a $100 million increase in U.S. spending.\nNovartis said it takes a value-based pricing approach and that it provided ICER with significant new clinical and health economic data that the group did not take into account.","news_type":1,"symbols_score_info":{"ABBV":0.9}},"isVote":1,"tweetType":1,"viewCount":1336,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871675121,"gmtCreate":1637070569594,"gmtModify":1637070844443,"author":{"id":"4100087245977920","authorId":"4100087245977920","name":"Unknownn","avatar":"https://static.tigerbbs.com/abc4f174c588f5a6be0547639a148c56","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100087245977920","authorIdStr":"4100087245977920"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871675121","repostId":"1115914926","repostType":4,"repost":{"id":"1115914926","kind":"news","pubTimestamp":1637065849,"share":"https://www.laohu8.com/m/news/1115914926?lang=zh_CN&edition=full","pubTime":"2021-11-16 20:30","market":"us","language":"en","title":"Report says drugmakers impose unjustified U.S. price increases; spending on AbbVie drug rises $1.4 billion<blockquote>报告称制药商在美国不合理地涨价；艾伯维药物支出增加14亿美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1115914926","media":"Reuters","summary":"Drugmakers hiked U.S. prices on seven of the 10 costliest prescription drugs in 2020 without justifi","content":"<p>Drugmakers hiked U.S. prices on seven of the 10 costliest prescription drugs in 2020 without justification, increasing drug spending by $1.67 billion, a U.S. group that reviews the value of medicines said on Tuesday.</p><p><blockquote>美国一个审查药品价值的组织周二表示，制药商在没有正当理由的情况下提高了2020年10种最昂贵处方药中的7种的美国价格，使药品支出增加了16.7亿美元。</blockquote></p><p> AbbVie Inc's(ABBV.N)widely used Humira rheumatoid arthritis drug accounted for the majority of the spending increase, with a net price increase of 9.6% leading to an almost $1.4 billion increase in U.S. spending.</p><p><blockquote>艾伯维公司（ABBV.N）广泛使用的Humira类风湿性关节炎药物占支出增长的大部分，净价格上涨9.6%，导致美国支出增加近14亿美元。</blockquote></p><p> The Boston-based Institute for Clinical and Economic Review (ICER) said in a report that after reviewing published studies and input from drug manufacturers it found no evidence of new clinical benefits to justify the price hikes.</p><p><blockquote>总部位于波士顿的临床和经济评论研究所（ICER）在一份报告中表示，在审查了已发表的研究和药品制造商的意见后，没有发现新的临床益处的证据来证明价格上涨的合理性。</blockquote></p><p> \"Several of these treatments have been on the market for many years, with scant evidence that they are any more effective than we understood them to be years ago when they cost far less,\" said ICER Chief Medical Officer David Rind.</p><p><blockquote>ICER首席医疗官David Rind表示：“其中一些治疗方法已经上市多年，几乎没有证据表明它们比我们多年前认为的更有效，当时它们的成本要低得多。”</blockquote></p><p> \"The most extreme of these is Humira, with an ever-escalating U.S. price that contrasts starkly to its falling price in every country where Humira currently faces biosimilar competition,\" he said in a statement. Humira received U.S. regulatory approval in 2002.</p><p><blockquote>他在一份声明中表示：“其中最极端的是修美乐，美国的价格不断上涨，与修美乐目前面临生物仿制药竞争的每个国家的价格下降形成鲜明对比。”Humira于2002年获得美国监管机构的批准。</blockquote></p><p> AbbVie said in a response to ICER that the report lacked context because ICER does not perform full value assessments and excludes evidence from smaller patient populations.</p><p><blockquote>艾伯维在回应ICER时表示，该报告缺乏背景，因为ICER没有进行全面的价值评估，并排除了来自较小患者群体的证据。</blockquote></p><p> The findings come as President Joe Biden and Democrats in Congress attempt to push through legislation that would lower drug prices by allowing the federal government to negotiate drug payments by Medicare, which covers Americans aged 65 and older.</p><p><blockquote>调查结果公布之际，美国总统乔·拜登和国会民主党人正试图推动立法，通过允许联邦政府通过医疗保险谈判药品支付来降低药品价格，医疗保险覆盖65岁及以上的美国人。</blockquote></p><p> The United States spends more than twice as much per person on drugs as other wealthy economies, about $1,500, for a total of around $350 billion in 2019.</p><p><blockquote>美国人均在毒品上的支出是其他富裕经济体的两倍多，约为1500美元，2019年总额约为3500亿美元。</blockquote></p><p> Novartis(NOVN.S)drug Promacta, which is used to treat the rare blood disorder severe aplastic anemia (SAA), saw the highest increase in net price at 14.1%, leading to a $100 million increase in U.S. spending.</p><p><blockquote>诺华（NOVN.S）用于治疗罕见血液疾病重度再生障碍性贫血（SAA）的药物Promacta净价涨幅最高，为14.1%，导致美国支出增加1亿美元。</blockquote></p><p> Novartis said it takes a value-based pricing approach and that it provided ICER with significant new clinical and health economic data that the group did not take into account.</p><p><blockquote>诺华表示，它采用基于价值的定价方法，并向ICER提供了该集团未考虑的重要新临床和健康经济数据。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Report says drugmakers impose unjustified U.S. price increases; spending on AbbVie drug rises $1.4 billion<blockquote>报告称制药商在美国不合理地涨价；艾伯维药物支出增加14亿美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReport says drugmakers impose unjustified U.S. price increases; spending on AbbVie drug rises $1.4 billion<blockquote>报告称制药商在美国不合理地涨价；艾伯维药物支出增加14亿美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-16 20:30</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Drugmakers hiked U.S. prices on seven of the 10 costliest prescription drugs in 2020 without justification, increasing drug spending by $1.67 billion, a U.S. group that reviews the value of medicines said on Tuesday.</p><p><blockquote>美国一个审查药品价值的组织周二表示，制药商在没有正当理由的情况下提高了2020年10种最昂贵处方药中的7种的美国价格，使药品支出增加了16.7亿美元。</blockquote></p><p> AbbVie Inc's(ABBV.N)widely used Humira rheumatoid arthritis drug accounted for the majority of the spending increase, with a net price increase of 9.6% leading to an almost $1.4 billion increase in U.S. spending.</p><p><blockquote>艾伯维公司（ABBV.N）广泛使用的Humira类风湿性关节炎药物占支出增长的大部分，净价格上涨9.6%，导致美国支出增加近14亿美元。</blockquote></p><p> The Boston-based Institute for Clinical and Economic Review (ICER) said in a report that after reviewing published studies and input from drug manufacturers it found no evidence of new clinical benefits to justify the price hikes.</p><p><blockquote>总部位于波士顿的临床和经济评论研究所（ICER）在一份报告中表示，在审查了已发表的研究和药品制造商的意见后，没有发现新的临床益处的证据来证明价格上涨的合理性。</blockquote></p><p> \"Several of these treatments have been on the market for many years, with scant evidence that they are any more effective than we understood them to be years ago when they cost far less,\" said ICER Chief Medical Officer David Rind.</p><p><blockquote>ICER首席医疗官David Rind表示：“其中一些治疗方法已经上市多年，几乎没有证据表明它们比我们多年前认为的更有效，当时它们的成本要低得多。”</blockquote></p><p> \"The most extreme of these is Humira, with an ever-escalating U.S. price that contrasts starkly to its falling price in every country where Humira currently faces biosimilar competition,\" he said in a statement. Humira received U.S. regulatory approval in 2002.</p><p><blockquote>他在一份声明中表示：“其中最极端的是修美乐，美国的价格不断上涨，与修美乐目前面临生物仿制药竞争的每个国家的价格下降形成鲜明对比。”Humira于2002年获得美国监管机构的批准。</blockquote></p><p> AbbVie said in a response to ICER that the report lacked context because ICER does not perform full value assessments and excludes evidence from smaller patient populations.</p><p><blockquote>艾伯维在回应ICER时表示，该报告缺乏背景，因为ICER没有进行全面的价值评估，并排除了来自较小患者群体的证据。</blockquote></p><p> The findings come as President Joe Biden and Democrats in Congress attempt to push through legislation that would lower drug prices by allowing the federal government to negotiate drug payments by Medicare, which covers Americans aged 65 and older.</p><p><blockquote>调查结果公布之际，美国总统乔·拜登和国会民主党人正试图推动立法，通过允许联邦政府通过医疗保险谈判药品支付来降低药品价格，医疗保险覆盖65岁及以上的美国人。</blockquote></p><p> The United States spends more than twice as much per person on drugs as other wealthy economies, about $1,500, for a total of around $350 billion in 2019.</p><p><blockquote>美国人均在毒品上的支出是其他富裕经济体的两倍多，约为1500美元，2019年总额约为3500亿美元。</blockquote></p><p> Novartis(NOVN.S)drug Promacta, which is used to treat the rare blood disorder severe aplastic anemia (SAA), saw the highest increase in net price at 14.1%, leading to a $100 million increase in U.S. spending.</p><p><blockquote>诺华（NOVN.S）用于治疗罕见血液疾病重度再生障碍性贫血（SAA）的药物Promacta净价涨幅最高，为14.1%，导致美国支出增加1亿美元。</blockquote></p><p> Novartis said it takes a value-based pricing approach and that it provided ICER with significant new clinical and health economic data that the group did not take into account.</p><p><blockquote>诺华表示，它采用基于价值的定价方法，并向ICER提供了该集团未考虑的重要新临床和健康经济数据。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/report-says-drugmakers-impose-unjustified-us-price-increases-spending-abbvie-2021-11-16/\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/report-says-drugmakers-impose-unjustified-us-price-increases-spending-abbvie-2021-11-16/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115914926","content_text":"Drugmakers hiked U.S. prices on seven of the 10 costliest prescription drugs in 2020 without justification, increasing drug spending by $1.67 billion, a U.S. group that reviews the value of medicines said on Tuesday.\nAbbVie Inc's(ABBV.N)widely used Humira rheumatoid arthritis drug accounted for the majority of the spending increase, with a net price increase of 9.6% leading to an almost $1.4 billion increase in U.S. spending.\nThe Boston-based Institute for Clinical and Economic Review (ICER) said in a report that after reviewing published studies and input from drug manufacturers it found no evidence of new clinical benefits to justify the price hikes.\n\"Several of these treatments have been on the market for many years, with scant evidence that they are any more effective than we understood them to be years ago when they cost far less,\" said ICER Chief Medical Officer David Rind.\n\"The most extreme of these is Humira, with an ever-escalating U.S. price that contrasts starkly to its falling price in every country where Humira currently faces biosimilar competition,\" he said in a statement. Humira received U.S. regulatory approval in 2002.\nAbbVie said in a response to ICER that the report lacked context because ICER does not perform full value assessments and excludes evidence from smaller patient populations.\nThe findings come as President Joe Biden and Democrats in Congress attempt to push through legislation that would lower drug prices by allowing the federal government to negotiate drug payments by Medicare, which covers Americans aged 65 and older.\nThe United States spends more than twice as much per person on drugs as other wealthy economies, about $1,500, for a total of around $350 billion in 2019.\nNovartis(NOVN.S)drug Promacta, which is used to treat the rare blood disorder severe aplastic anemia (SAA), saw the highest increase in net price at 14.1%, leading to a $100 million increase in U.S. spending.\nNovartis said it takes a value-based pricing approach and that it provided ICER with significant new clinical and health economic data that the group did not take into account.","news_type":1,"symbols_score_info":{"ABBV":0.9}},"isVote":1,"tweetType":1,"viewCount":1361,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":600716496,"gmtCreate":1638197483029,"gmtModify":1638197483104,"author":{"id":"4100087245977920","authorId":"4100087245977920","name":"Unknownn","avatar":"https://static.tigerbbs.com/abc4f174c588f5a6be0547639a148c56","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100087245977920","authorIdStr":"4100087245977920"},"themes":[],"htmlText":"Up more","listText":"Up more","text":"Up more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/600716496","repostId":"1182524223","repostType":4,"repost":{"id":"1182524223","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638197006,"share":"https://www.laohu8.com/m/news/1182524223?lang=zh_CN&edition=full","pubTime":"2021-11-29 22:43","market":"us","language":"en","title":"Big tech shares jumped in morning trading<blockquote>大型科技股早盘上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1182524223","media":"Tiger Newspress","summary":"Big tech shares jumped in morning trading.Apple,Microsoft,Amazon,Alphabet and Meta Platforms climbed","content":"<p>Big tech shares jumped in morning trading.Apple,Microsoft,Amazon,Alphabet&nbsp;and&nbsp;Meta&nbsp;Platforms&nbsp;climbed between 1% and 2%.</p><p><blockquote>大型科技股早盘上涨。苹果、微软、亚马逊、Alphabet和Meta Platforms上涨1%至2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/e646cfb67f62c007db16ed52e6712cd4\" tg-width=\"406\" tg-height=\"299\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Big tech shares jumped in morning trading<blockquote>大型科技股早盘上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBig tech shares jumped in morning trading<blockquote>大型科技股早盘上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 22:43</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Big tech shares jumped in morning trading.Apple,Microsoft,Amazon,Alphabet&nbsp;and&nbsp;Meta&nbsp;Platforms&nbsp;climbed between 1% and 2%.</p><p><blockquote>大型科技股早盘上涨。苹果、微软、亚马逊、Alphabet和Meta Platforms上涨1%至2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/e646cfb67f62c007db16ed52e6712cd4\" tg-width=\"406\" tg-height=\"299\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","FB":"ProShares S&P 500 Dynamic Buffer ETF","AAPL":"苹果","GOOGL":"谷歌A","MSFT":"微软"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182524223","content_text":"Big tech shares jumped in morning trading.Apple,Microsoft,Amazon,Alphabet and Meta Platforms climbed between 1% and 2%.","news_type":1,"symbols_score_info":{"AAPL":0.9,"GOOGL":0.9,"AMZN":0.9,"FB":0.9,"MSFT":0.9}},"isVote":1,"tweetType":1,"viewCount":1080,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871675121,"gmtCreate":1637070569594,"gmtModify":1637070844443,"author":{"id":"4100087245977920","authorId":"4100087245977920","name":"Unknownn","avatar":"https://static.tigerbbs.com/abc4f174c588f5a6be0547639a148c56","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100087245977920","authorIdStr":"4100087245977920"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871675121","repostId":"1115914926","repostType":4,"repost":{"id":"1115914926","kind":"news","pubTimestamp":1637065849,"share":"https://www.laohu8.com/m/news/1115914926?lang=zh_CN&edition=full","pubTime":"2021-11-16 20:30","market":"us","language":"en","title":"Report says drugmakers impose unjustified U.S. price increases; spending on AbbVie drug rises $1.4 billion<blockquote>报告称制药商在美国不合理地涨价；艾伯维药物支出增加14亿美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1115914926","media":"Reuters","summary":"Drugmakers hiked U.S. prices on seven of the 10 costliest prescription drugs in 2020 without justifi","content":"<p>Drugmakers hiked U.S. prices on seven of the 10 costliest prescription drugs in 2020 without justification, increasing drug spending by $1.67 billion, a U.S. group that reviews the value of medicines said on Tuesday.</p><p><blockquote>美国一个审查药品价值的组织周二表示，制药商在没有正当理由的情况下提高了2020年10种最昂贵处方药中的7种的美国价格，使药品支出增加了16.7亿美元。</blockquote></p><p> AbbVie Inc's(ABBV.N)widely used Humira rheumatoid arthritis drug accounted for the majority of the spending increase, with a net price increase of 9.6% leading to an almost $1.4 billion increase in U.S. spending.</p><p><blockquote>艾伯维公司（ABBV.N）广泛使用的Humira类风湿性关节炎药物占支出增长的大部分，净价格上涨9.6%，导致美国支出增加近14亿美元。</blockquote></p><p> The Boston-based Institute for Clinical and Economic Review (ICER) said in a report that after reviewing published studies and input from drug manufacturers it found no evidence of new clinical benefits to justify the price hikes.</p><p><blockquote>总部位于波士顿的临床和经济评论研究所（ICER）在一份报告中表示，在审查了已发表的研究和药品制造商的意见后，没有发现新的临床益处的证据来证明价格上涨的合理性。</blockquote></p><p> \"Several of these treatments have been on the market for many years, with scant evidence that they are any more effective than we understood them to be years ago when they cost far less,\" said ICER Chief Medical Officer David Rind.</p><p><blockquote>ICER首席医疗官David Rind表示：“其中一些治疗方法已经上市多年，几乎没有证据表明它们比我们多年前认为的更有效，当时它们的成本要低得多。”</blockquote></p><p> \"The most extreme of these is Humira, with an ever-escalating U.S. price that contrasts starkly to its falling price in every country where Humira currently faces biosimilar competition,\" he said in a statement. Humira received U.S. regulatory approval in 2002.</p><p><blockquote>他在一份声明中表示：“其中最极端的是修美乐，美国的价格不断上涨，与修美乐目前面临生物仿制药竞争的每个国家的价格下降形成鲜明对比。”Humira于2002年获得美国监管机构的批准。</blockquote></p><p> AbbVie said in a response to ICER that the report lacked context because ICER does not perform full value assessments and excludes evidence from smaller patient populations.</p><p><blockquote>艾伯维在回应ICER时表示，该报告缺乏背景，因为ICER没有进行全面的价值评估，并排除了来自较小患者群体的证据。</blockquote></p><p> The findings come as President Joe Biden and Democrats in Congress attempt to push through legislation that would lower drug prices by allowing the federal government to negotiate drug payments by Medicare, which covers Americans aged 65 and older.</p><p><blockquote>调查结果公布之际，美国总统乔·拜登和国会民主党人正试图推动立法，通过允许联邦政府通过医疗保险谈判药品支付来降低药品价格，医疗保险覆盖65岁及以上的美国人。</blockquote></p><p> The United States spends more than twice as much per person on drugs as other wealthy economies, about $1,500, for a total of around $350 billion in 2019.</p><p><blockquote>美国人均在毒品上的支出是其他富裕经济体的两倍多，约为1500美元，2019年总额约为3500亿美元。</blockquote></p><p> Novartis(NOVN.S)drug Promacta, which is used to treat the rare blood disorder severe aplastic anemia (SAA), saw the highest increase in net price at 14.1%, leading to a $100 million increase in U.S. spending.</p><p><blockquote>诺华（NOVN.S）用于治疗罕见血液疾病重度再生障碍性贫血（SAA）的药物Promacta净价涨幅最高，为14.1%，导致美国支出增加1亿美元。</blockquote></p><p> Novartis said it takes a value-based pricing approach and that it provided ICER with significant new clinical and health economic data that the group did not take into account.</p><p><blockquote>诺华表示，它采用基于价值的定价方法，并向ICER提供了该集团未考虑的重要新临床和健康经济数据。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Report says drugmakers impose unjustified U.S. price increases; spending on AbbVie drug rises $1.4 billion<blockquote>报告称制药商在美国不合理地涨价；艾伯维药物支出增加14亿美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReport says drugmakers impose unjustified U.S. price increases; spending on AbbVie drug rises $1.4 billion<blockquote>报告称制药商在美国不合理地涨价；艾伯维药物支出增加14亿美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-16 20:30</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Drugmakers hiked U.S. prices on seven of the 10 costliest prescription drugs in 2020 without justification, increasing drug spending by $1.67 billion, a U.S. group that reviews the value of medicines said on Tuesday.</p><p><blockquote>美国一个审查药品价值的组织周二表示，制药商在没有正当理由的情况下提高了2020年10种最昂贵处方药中的7种的美国价格，使药品支出增加了16.7亿美元。</blockquote></p><p> AbbVie Inc's(ABBV.N)widely used Humira rheumatoid arthritis drug accounted for the majority of the spending increase, with a net price increase of 9.6% leading to an almost $1.4 billion increase in U.S. spending.</p><p><blockquote>艾伯维公司（ABBV.N）广泛使用的Humira类风湿性关节炎药物占支出增长的大部分，净价格上涨9.6%，导致美国支出增加近14亿美元。</blockquote></p><p> The Boston-based Institute for Clinical and Economic Review (ICER) said in a report that after reviewing published studies and input from drug manufacturers it found no evidence of new clinical benefits to justify the price hikes.</p><p><blockquote>总部位于波士顿的临床和经济评论研究所（ICER）在一份报告中表示，在审查了已发表的研究和药品制造商的意见后，没有发现新的临床益处的证据来证明价格上涨的合理性。</blockquote></p><p> \"Several of these treatments have been on the market for many years, with scant evidence that they are any more effective than we understood them to be years ago when they cost far less,\" said ICER Chief Medical Officer David Rind.</p><p><blockquote>ICER首席医疗官David Rind表示：“其中一些治疗方法已经上市多年，几乎没有证据表明它们比我们多年前认为的更有效，当时它们的成本要低得多。”</blockquote></p><p> \"The most extreme of these is Humira, with an ever-escalating U.S. price that contrasts starkly to its falling price in every country where Humira currently faces biosimilar competition,\" he said in a statement. Humira received U.S. regulatory approval in 2002.</p><p><blockquote>他在一份声明中表示：“其中最极端的是修美乐，美国的价格不断上涨，与修美乐目前面临生物仿制药竞争的每个国家的价格下降形成鲜明对比。”Humira于2002年获得美国监管机构的批准。</blockquote></p><p> AbbVie said in a response to ICER that the report lacked context because ICER does not perform full value assessments and excludes evidence from smaller patient populations.</p><p><blockquote>艾伯维在回应ICER时表示，该报告缺乏背景，因为ICER没有进行全面的价值评估，并排除了来自较小患者群体的证据。</blockquote></p><p> The findings come as President Joe Biden and Democrats in Congress attempt to push through legislation that would lower drug prices by allowing the federal government to negotiate drug payments by Medicare, which covers Americans aged 65 and older.</p><p><blockquote>调查结果公布之际，美国总统乔·拜登和国会民主党人正试图推动立法，通过允许联邦政府通过医疗保险谈判药品支付来降低药品价格，医疗保险覆盖65岁及以上的美国人。</blockquote></p><p> The United States spends more than twice as much per person on drugs as other wealthy economies, about $1,500, for a total of around $350 billion in 2019.</p><p><blockquote>美国人均在毒品上的支出是其他富裕经济体的两倍多，约为1500美元，2019年总额约为3500亿美元。</blockquote></p><p> Novartis(NOVN.S)drug Promacta, which is used to treat the rare blood disorder severe aplastic anemia (SAA), saw the highest increase in net price at 14.1%, leading to a $100 million increase in U.S. spending.</p><p><blockquote>诺华（NOVN.S）用于治疗罕见血液疾病重度再生障碍性贫血（SAA）的药物Promacta净价涨幅最高，为14.1%，导致美国支出增加1亿美元。</blockquote></p><p> Novartis said it takes a value-based pricing approach and that it provided ICER with significant new clinical and health economic data that the group did not take into account.</p><p><blockquote>诺华表示，它采用基于价值的定价方法，并向ICER提供了该集团未考虑的重要新临床和健康经济数据。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/report-says-drugmakers-impose-unjustified-us-price-increases-spending-abbvie-2021-11-16/\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/report-says-drugmakers-impose-unjustified-us-price-increases-spending-abbvie-2021-11-16/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115914926","content_text":"Drugmakers hiked U.S. prices on seven of the 10 costliest prescription drugs in 2020 without justification, increasing drug spending by $1.67 billion, a U.S. group that reviews the value of medicines said on Tuesday.\nAbbVie Inc's(ABBV.N)widely used Humira rheumatoid arthritis drug accounted for the majority of the spending increase, with a net price increase of 9.6% leading to an almost $1.4 billion increase in U.S. spending.\nThe Boston-based Institute for Clinical and Economic Review (ICER) said in a report that after reviewing published studies and input from drug manufacturers it found no evidence of new clinical benefits to justify the price hikes.\n\"Several of these treatments have been on the market for many years, with scant evidence that they are any more effective than we understood them to be years ago when they cost far less,\" said ICER Chief Medical Officer David Rind.\n\"The most extreme of these is Humira, with an ever-escalating U.S. price that contrasts starkly to its falling price in every country where Humira currently faces biosimilar competition,\" he said in a statement. Humira received U.S. regulatory approval in 2002.\nAbbVie said in a response to ICER that the report lacked context because ICER does not perform full value assessments and excludes evidence from smaller patient populations.\nThe findings come as President Joe Biden and Democrats in Congress attempt to push through legislation that would lower drug prices by allowing the federal government to negotiate drug payments by Medicare, which covers Americans aged 65 and older.\nThe United States spends more than twice as much per person on drugs as other wealthy economies, about $1,500, for a total of around $350 billion in 2019.\nNovartis(NOVN.S)drug Promacta, which is used to treat the rare blood disorder severe aplastic anemia (SAA), saw the highest increase in net price at 14.1%, leading to a $100 million increase in U.S. spending.\nNovartis said it takes a value-based pricing approach and that it provided ICER with significant new clinical and health economic data that the group did not take into account.","news_type":1,"symbols_score_info":{"ABBV":0.9}},"isVote":1,"tweetType":1,"viewCount":1361,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871674052,"gmtCreate":1637070595727,"gmtModify":1637070872794,"author":{"id":"4100087245977920","authorId":"4100087245977920","name":"Unknownn","avatar":"https://static.tigerbbs.com/abc4f174c588f5a6be0547639a148c56","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100087245977920","authorIdStr":"4100087245977920"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871674052","repostId":"1115914926","repostType":4,"repost":{"id":"1115914926","kind":"news","pubTimestamp":1637065849,"share":"https://www.laohu8.com/m/news/1115914926?lang=zh_CN&edition=full","pubTime":"2021-11-16 20:30","market":"us","language":"en","title":"Report says drugmakers impose unjustified U.S. price increases; spending on AbbVie drug rises $1.4 billion<blockquote>报告称制药商在美国不合理地涨价；艾伯维药物支出增加14亿美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1115914926","media":"Reuters","summary":"Drugmakers hiked U.S. prices on seven of the 10 costliest prescription drugs in 2020 without justifi","content":"<p>Drugmakers hiked U.S. prices on seven of the 10 costliest prescription drugs in 2020 without justification, increasing drug spending by $1.67 billion, a U.S. group that reviews the value of medicines said on Tuesday.</p><p><blockquote>美国一个审查药品价值的组织周二表示，制药商在没有正当理由的情况下提高了2020年10种最昂贵处方药中的7种的美国价格，使药品支出增加了16.7亿美元。</blockquote></p><p> AbbVie Inc's(ABBV.N)widely used Humira rheumatoid arthritis drug accounted for the majority of the spending increase, with a net price increase of 9.6% leading to an almost $1.4 billion increase in U.S. spending.</p><p><blockquote>艾伯维公司（ABBV.N）广泛使用的Humira类风湿性关节炎药物占支出增长的大部分，净价格上涨9.6%，导致美国支出增加近14亿美元。</blockquote></p><p> The Boston-based Institute for Clinical and Economic Review (ICER) said in a report that after reviewing published studies and input from drug manufacturers it found no evidence of new clinical benefits to justify the price hikes.</p><p><blockquote>总部位于波士顿的临床和经济评论研究所（ICER）在一份报告中表示，在审查了已发表的研究和药品制造商的意见后，没有发现新的临床益处的证据来证明价格上涨的合理性。</blockquote></p><p> \"Several of these treatments have been on the market for many years, with scant evidence that they are any more effective than we understood them to be years ago when they cost far less,\" said ICER Chief Medical Officer David Rind.</p><p><blockquote>ICER首席医疗官David Rind表示：“其中一些治疗方法已经上市多年，几乎没有证据表明它们比我们多年前认为的更有效，当时它们的成本要低得多。”</blockquote></p><p> \"The most extreme of these is Humira, with an ever-escalating U.S. price that contrasts starkly to its falling price in every country where Humira currently faces biosimilar competition,\" he said in a statement. Humira received U.S. regulatory approval in 2002.</p><p><blockquote>他在一份声明中表示：“其中最极端的是修美乐，美国的价格不断上涨，与修美乐目前面临生物仿制药竞争的每个国家的价格下降形成鲜明对比。”Humira于2002年获得美国监管机构的批准。</blockquote></p><p> AbbVie said in a response to ICER that the report lacked context because ICER does not perform full value assessments and excludes evidence from smaller patient populations.</p><p><blockquote>艾伯维在回应ICER时表示，该报告缺乏背景，因为ICER没有进行全面的价值评估，并排除了来自较小患者群体的证据。</blockquote></p><p> The findings come as President Joe Biden and Democrats in Congress attempt to push through legislation that would lower drug prices by allowing the federal government to negotiate drug payments by Medicare, which covers Americans aged 65 and older.</p><p><blockquote>调查结果公布之际，美国总统乔·拜登和国会民主党人正试图推动立法，通过允许联邦政府通过医疗保险谈判药品支付来降低药品价格，医疗保险覆盖65岁及以上的美国人。</blockquote></p><p> The United States spends more than twice as much per person on drugs as other wealthy economies, about $1,500, for a total of around $350 billion in 2019.</p><p><blockquote>美国人均在毒品上的支出是其他富裕经济体的两倍多，约为1500美元，2019年总额约为3500亿美元。</blockquote></p><p> Novartis(NOVN.S)drug Promacta, which is used to treat the rare blood disorder severe aplastic anemia (SAA), saw the highest increase in net price at 14.1%, leading to a $100 million increase in U.S. spending.</p><p><blockquote>诺华（NOVN.S）用于治疗罕见血液疾病重度再生障碍性贫血（SAA）的药物Promacta净价涨幅最高，为14.1%，导致美国支出增加1亿美元。</blockquote></p><p> Novartis said it takes a value-based pricing approach and that it provided ICER with significant new clinical and health economic data that the group did not take into account.</p><p><blockquote>诺华表示，它采用基于价值的定价方法，并向ICER提供了该集团未考虑的重要新临床和健康经济数据。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Report says drugmakers impose unjustified U.S. price increases; spending on AbbVie drug rises $1.4 billion<blockquote>报告称制药商在美国不合理地涨价；艾伯维药物支出增加14亿美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReport says drugmakers impose unjustified U.S. price increases; spending on AbbVie drug rises $1.4 billion<blockquote>报告称制药商在美国不合理地涨价；艾伯维药物支出增加14亿美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-16 20:30</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Drugmakers hiked U.S. prices on seven of the 10 costliest prescription drugs in 2020 without justification, increasing drug spending by $1.67 billion, a U.S. group that reviews the value of medicines said on Tuesday.</p><p><blockquote>美国一个审查药品价值的组织周二表示，制药商在没有正当理由的情况下提高了2020年10种最昂贵处方药中的7种的美国价格，使药品支出增加了16.7亿美元。</blockquote></p><p> AbbVie Inc's(ABBV.N)widely used Humira rheumatoid arthritis drug accounted for the majority of the spending increase, with a net price increase of 9.6% leading to an almost $1.4 billion increase in U.S. spending.</p><p><blockquote>艾伯维公司（ABBV.N）广泛使用的Humira类风湿性关节炎药物占支出增长的大部分，净价格上涨9.6%，导致美国支出增加近14亿美元。</blockquote></p><p> The Boston-based Institute for Clinical and Economic Review (ICER) said in a report that after reviewing published studies and input from drug manufacturers it found no evidence of new clinical benefits to justify the price hikes.</p><p><blockquote>总部位于波士顿的临床和经济评论研究所（ICER）在一份报告中表示，在审查了已发表的研究和药品制造商的意见后，没有发现新的临床益处的证据来证明价格上涨的合理性。</blockquote></p><p> \"Several of these treatments have been on the market for many years, with scant evidence that they are any more effective than we understood them to be years ago when they cost far less,\" said ICER Chief Medical Officer David Rind.</p><p><blockquote>ICER首席医疗官David Rind表示：“其中一些治疗方法已经上市多年，几乎没有证据表明它们比我们多年前认为的更有效，当时它们的成本要低得多。”</blockquote></p><p> \"The most extreme of these is Humira, with an ever-escalating U.S. price that contrasts starkly to its falling price in every country where Humira currently faces biosimilar competition,\" he said in a statement. Humira received U.S. regulatory approval in 2002.</p><p><blockquote>他在一份声明中表示：“其中最极端的是修美乐，美国的价格不断上涨，与修美乐目前面临生物仿制药竞争的每个国家的价格下降形成鲜明对比。”Humira于2002年获得美国监管机构的批准。</blockquote></p><p> AbbVie said in a response to ICER that the report lacked context because ICER does not perform full value assessments and excludes evidence from smaller patient populations.</p><p><blockquote>艾伯维在回应ICER时表示，该报告缺乏背景，因为ICER没有进行全面的价值评估，并排除了来自较小患者群体的证据。</blockquote></p><p> The findings come as President Joe Biden and Democrats in Congress attempt to push through legislation that would lower drug prices by allowing the federal government to negotiate drug payments by Medicare, which covers Americans aged 65 and older.</p><p><blockquote>调查结果公布之际，美国总统乔·拜登和国会民主党人正试图推动立法，通过允许联邦政府通过医疗保险谈判药品支付来降低药品价格，医疗保险覆盖65岁及以上的美国人。</blockquote></p><p> The United States spends more than twice as much per person on drugs as other wealthy economies, about $1,500, for a total of around $350 billion in 2019.</p><p><blockquote>美国人均在毒品上的支出是其他富裕经济体的两倍多，约为1500美元，2019年总额约为3500亿美元。</blockquote></p><p> Novartis(NOVN.S)drug Promacta, which is used to treat the rare blood disorder severe aplastic anemia (SAA), saw the highest increase in net price at 14.1%, leading to a $100 million increase in U.S. spending.</p><p><blockquote>诺华（NOVN.S）用于治疗罕见血液疾病重度再生障碍性贫血（SAA）的药物Promacta净价涨幅最高，为14.1%，导致美国支出增加1亿美元。</blockquote></p><p> Novartis said it takes a value-based pricing approach and that it provided ICER with significant new clinical and health economic data that the group did not take into account.</p><p><blockquote>诺华表示，它采用基于价值的定价方法，并向ICER提供了该集团未考虑的重要新临床和健康经济数据。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/report-says-drugmakers-impose-unjustified-us-price-increases-spending-abbvie-2021-11-16/\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/report-says-drugmakers-impose-unjustified-us-price-increases-spending-abbvie-2021-11-16/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115914926","content_text":"Drugmakers hiked U.S. prices on seven of the 10 costliest prescription drugs in 2020 without justification, increasing drug spending by $1.67 billion, a U.S. group that reviews the value of medicines said on Tuesday.\nAbbVie Inc's(ABBV.N)widely used Humira rheumatoid arthritis drug accounted for the majority of the spending increase, with a net price increase of 9.6% leading to an almost $1.4 billion increase in U.S. spending.\nThe Boston-based Institute for Clinical and Economic Review (ICER) said in a report that after reviewing published studies and input from drug manufacturers it found no evidence of new clinical benefits to justify the price hikes.\n\"Several of these treatments have been on the market for many years, with scant evidence that they are any more effective than we understood them to be years ago when they cost far less,\" said ICER Chief Medical Officer David Rind.\n\"The most extreme of these is Humira, with an ever-escalating U.S. price that contrasts starkly to its falling price in every country where Humira currently faces biosimilar competition,\" he said in a statement. Humira received U.S. regulatory approval in 2002.\nAbbVie said in a response to ICER that the report lacked context because ICER does not perform full value assessments and excludes evidence from smaller patient populations.\nThe findings come as President Joe Biden and Democrats in Congress attempt to push through legislation that would lower drug prices by allowing the federal government to negotiate drug payments by Medicare, which covers Americans aged 65 and older.\nThe United States spends more than twice as much per person on drugs as other wealthy economies, about $1,500, for a total of around $350 billion in 2019.\nNovartis(NOVN.S)drug Promacta, which is used to treat the rare blood disorder severe aplastic anemia (SAA), saw the highest increase in net price at 14.1%, leading to a $100 million increase in U.S. spending.\nNovartis said it takes a value-based pricing approach and that it provided ICER with significant new clinical and health economic data that the group did not take into account.","news_type":1,"symbols_score_info":{"ABBV":0.9}},"isVote":1,"tweetType":1,"viewCount":1336,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}